This guidance is a Cancer Drugs Fund reconsideration of bosutinib for previously treated chronic myeloid leukaemia (TA299) and replaces this guidance. Bosutinib was previously available to patients only through the Cancer Drugs Fund, but will now be routinely available on the NHS because the company that markets it has lowered the price and so it is now considered better value for money.